Paper Details

  1. Home
  2. Paper Details

[Cutaneous adverse events of telaprevir/peginterferon/ribavirin therapy for chronic hepatitis C: A multicenter prospective cohort study].

Author: BottaD, Gaudy-MarquesteC, GrobJ-J, LorcyS, ManciniJ, OuliesV, PortalI, QuilesN, RichardM-A

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Overview

This prospective observational study of 48 patients assessed the incidence of skin eruption and clinical characteristics of mucocutaneous adverse events associated with telaprevir treatment. The incidence of skin eruption was 58.4%, but most cases were mild. Telaprevir was discontinued in 6% of patients due to severe rash.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Telaprevir, sale of which was suspended, has been approved in combination with pegylated interferon and ribavirin (triple therapy) in the treatment of chronic hepatitis C virus (HCV). Skin eruptions and isolated cases of severe cutaneous adverse reactions (SCAR) have been reported. AIMS...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.annder.2016.02.028

データ提供：米国国立医学図書館（NLM）

Telaprevir: Navigating the Skin Side Effects

The desert of chronic hepatitis C (HCV) treatment can be a challenging one, with patients navigating the complexities of therapy and potential side effects. This study investigates the incidence and characteristics of cutaneous adverse events (AEs) associated with telaprevir, a drug used in combination therapy for HCV.

A Rough Patch on the Road to Recovery

The study highlights the high incidence of skin eruptions associated with telaprevir, but emphasizes that most are mild in intensity. However, the authors acknowledge the potential for severe cutaneous adverse reactions (SCARs), underscoring the need for careful monitoring and prompt intervention. It's like encountering a patch of rough terrain on a desert journey – vigilance and adaptability are essential for navigating safely.

Managing the Journey

This research emphasizes the importance of close dermatological follow-up for patients receiving telaprevir therapy. The authors recommend early detection and management of skin AEs to minimize the risk of severe complications. This approach ensures a smoother and safer journey through the desert of HCV treatment.

Dr.Camel's Conclusion

This research shines a light on the importance of managing the potential side effects of HCV therapies. Like a skilled desert guide, clinicians must be aware of the potential challenges and prepare patients for a successful journey toward recovery.

Date :
  1. Date Completed 2017-06-14
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

27161648

DOI: Digital Object Identifier

10.1016/j.annder.2016.02.028

Related Literature

Article Analysis
・Side Effects of telaprevir
SNS
PICO Info
in preparation
Languages

French

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.